Pivotal phase III trial of ezatiostat for low to intermediate-1 risk myelodysplastic syndromes.

Trial Profile

Pivotal phase III trial of ezatiostat for low to intermediate-1 risk myelodysplastic syndromes.

Planning
Phase of Trial: Phase III

Latest Information Update: 15 Mar 2013

At a glance

  • Drugs Ezatiostat (Primary)
  • Indications Myelodysplastic syndromes
  • Focus Therapeutic Use
  • Sponsors Telik
  • Most Recent Events

    • 15 Mar 2013 Telik needs to secure funding through the establishment of a corporate partnership and licensing agreement, funding from a non-profit agency, or other financing source, in order to initiate this trial, according to a company media release.
    • 27 Jan 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top